Literature DB >> 15070854

Growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-gamma ligands.

Fausto Bogazzi1, Federica Ultimieri, Francesco Raggi, Dania Russo, Renato Vanacore, Chiara Guida, Sandra Brogioni, Chiara Cosci, Maurizio Gasperi, Luigi Bartalena, Enio Martino.   

Abstract

GH has antiapoptotic effects on several cells. However, the antiapoptotic mechanisms of GH on colonic mucosa cells are not completely understood. Peroxisome proliferator activated receptor-gamma (PPARgamma) activation enhances apoptosis, and a link between GH and PPARgamma in the colonic epithelium of acromegalic patients has been suggested. We investigated the effects of GH and of PPARgamma ligands on apoptosis in colonic cancer cell lines. Colonic cells showed specific binding sites for GH, and after exposure to 0.05-50 nm GH, their apoptosis reduced by 45%. The antiapoptotic effect was due to either GH directly or GH-dependent local production of IGF-1. A 55-85% reduction of PPARgamma expression was observed in GH-treated cells, compared with controls (P < 0.05). However, treatment of the cells with 1-50 microm ciglitazone (cig), induced apoptosis and reverted the antiapoptotic effects of GH by increasing the programmed cell death up to 3.5-fold at 30 min and up to 1.7-fold at 24 h. Expression of Bcl-2 and TNF-related apoptosis-induced ligand was not affected by either GH or cig treatment, whereas GH reduced the expression of Bax, which was increased by cig treatment. In addition, GH increased the expression of signal transducer and activator of transcription 5b, which might be involved in the down-regulation of PPARgamma expression. In conclusion, GH may exert a direct antiapoptotic effect on colonic cells, through an increased expression of signal transducer and activator of transcription 5b and a reduction of Bax and PPARgamma. The reduced GH-dependent apoptosis can be overcome by PPARgamma ligands, which might be useful chemopreventive agents in acromegalic patients, who have an increased colonic polyps prevalence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070854     DOI: 10.1210/en.2004-0225

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.

Authors:  F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

2.  Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.

Authors:  Erica Gentilin; Mariella Minoia; Marta Bondanelli; Federico Tagliati; Ettore C Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2016-09-01       Impact factor: 3.633

3.  Comparison of colonoscopy and fecal occult blood testing as a first-line screening of colonic lesions in patients with newly diagnosed acromegaly.

Authors:  F Bogazzi; M Lombardi; I Scattina; C Urbani; E Marciano; A Costa; P Pepe; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

4.  Abrogation of GH action in Kupffer cells results in increased hepatic CD36 expression and exaggerated nonalcoholic fatty liver disease.

Authors:  Sherry Zhang; Chunxia Lu; Arun K Das; Anil K Pasupulati; Ram K Menon
Journal:  Growth Horm IGF Res       Date:  2018-10-04       Impact factor: 2.372

5.  Excess growth hormone suppresses DNA damage repair in epithelial cells.

Authors:  Vera Chesnokova; Svetlana Zonis; Robert Barrett; Hiraku Kameda; Kolja Wawrowsky; Anat Ben-Shlomo; Masaaki Yamamoto; John Gleeson; Catherine Bresee; Vera Gorbunova; Shlomo Melmed
Journal:  JCI Insight       Date:  2019-02-07

Review 6.  Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer.

Authors:  John J Kopchick; Reetobrata Basu; Darlene E Berryman; Jens O L Jorgensen; Gudmundur Johannsson; Vishwajeet Puri
Journal:  Nat Rev Endocrinol       Date:  2022-06-24       Impact factor: 47.564

7.  Adrenal morpho-functional alterations in patients with acromegaly.

Authors:  C Scaroni; R Selice; S Benedini; E De Menis; M Arosio; C Ronchi; M Gasperi; L Manetti; G Arnaldi; B Polenta; M Boscaro; N Albiger; E Martino; F Mantero
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

8.  Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland.

Authors:  Francesco Raggi; Dania Russo; Claudio Urbani; Chiara Sardella; Luca Manetti; Daniele Cappellani; Isabella Lupi; Luca Tomisti; Enio Martino; Claudio Marcocci; Fausto Bogazzi
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

9.  The Impact of Growth Hormone Therapy on the Apoptosis Assessment in CD34+ Hematopoietic Cells from Children with Growth Hormone Deficiency.

Authors:  Miłosz Piotr Kawa; Iwona Stecewicz; Katarzyna Piecyk; Edyta Paczkowska; Dorota Rogińska; Anna Sobuś; Karolina Łuczkowska; Ewa Pius-Sadowska; Elżbieta Gawrych; Elżbieta Petriczko; Mieczysław Walczak; Bogusław Machaliński
Journal:  Int J Mol Sci       Date:  2017-01-07       Impact factor: 5.923

10.  The effects of growth hormone on therapy resistance in cancer.

Authors:  Reetobrata Basu; John J Kopchick
Journal:  Cancer Drug Resist       Date:  2019-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.